Managing R/R Multiple Myeloma: Current Strategies and Future Directions in Community Practice
The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized treatment approaches, incorporating novel therapies such as CAR T-cell therapy while carefully monitoring for and managing toxicities through established protocols. Key considerations include implementing systematic toxicity management strategies, maintaining long-term patient monitoring, and staying informed about emerging therapeutic options. The field is evolving with promising novel agents and combination approaches being investigated, particularly for patients who progress after initial treatments.
Video content above is prompted by the following:
- What are the key strategies that community-based clinicians can leverage to effectively manage and support patients with R/R multiple myeloma?
- What toxicity mitigation strategies would you consider for patients who receive CAR T for 3L R/R multiple myeloma?
- What recommendations can you share for community providers on long-term monitoring of CAR T in patients with R/R MM?
- What is the future for the treatment of R/R multiple myeloma?
- What novel therapeutic strategies or combination approaches are being investigated for patients with multiple myeloma who progress beyond early lines of therapy?
Peers Evaluate CAR T Referral and Bridging Process for Early Relapsed Multiple Myeloma
December 26th 2024During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with lenalidomide-refractory multiple myeloma after 1 prior line of therapy.
Read More
